One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
Figure 2
Change in VA score (ETDRS chart) from baseline (BL) to month 12 (on-treatment population, ). Values are shown as .
